Perrigo (PRGO) Income from Continuing Operations (2012 - 2026)
Perrigo (PRGO) posted quarterly Income from Continuing Operations of 389800000.0 for Q1 2026, down 389900.0% year-over-year from N/an in Q1 2025, and up 72.44% quarter-over-quarter from 1414600000.0 in Q4 2025.
Perrigo (PRGO) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Perrigo (PRGO) has reported Income from Continuing Operations for 15 consecutive years, with 389800000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 389900.0% year-over-year to 389800000.0; the TTM figure through Mar 2026 stood at 1792200000.0 (down 988.16% YoY), while the FY2025 annual figure was 1402300000.0, down 772.62% from the prior year.
- Income from Continuing Operations advanced to 389800000.0 in Q1 2026 per PRGO's latest filing, from 1414600000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 15400000.0 in Q3 2023 and bottomed at 1414600000.0 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 122841176.47 across 5 years, with a median of 12700000.0 in 2022.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations surged 472.73% — and 2026, when it tumbled 389900.0%.
- Perrigo's Income from Continuing Operations stood at 12700000.0 in 2022, then plunged by 118.11% to 27700000.0 in 2023, then plunged by 49.82% to 41500000.0 in 2024, then sank by 3308.67% to 1414600000.0 in 2025, then soared by 72.44% to 389800000.0 in 2026.
- Business Quant data shows PRGO's Income from Continuing Operations at 389800000.0 in Q1 2026, 1414600000.0 in Q4 2025, and 12700000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Perrigo | 1.91 Bn | 1.51 Bn | 313.90 Mn | 88.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | 88.50 Mn |
| Mar 28, 2026 | -389.80 Mn |
| Dec 31, 2025 | -1.41 Bn |
| Sep 27, 2025 | 12.70 Mn |
| Jun 28, 2025 | -500,000.00 |
| Mar 29, 2025 | 100,000.00 |
| Dec 31, 2024 | -41.50 Mn |
| Sep 28, 2024 | -17.60 Mn |
| Jun 29, 2024 | -105.70 Mn |
| Mar 30, 2024 | 4.10 Mn |
| Dec 31, 2023 | -27.70 Mn |
| Sep 30, 2023 | 15.40 Mn |
| Jul 1, 2023 | 8.90 Mn |
| Apr 1, 2023 | -1.10 Mn |
| Dec 31, 2022 | -12.70 Mn |
| Oct 1, 2022 | -52.10 Mn |
| Jul 2, 2022 | -64.90 Mn |
| Apr 2, 2022 | -1.30 Mn |
| Dec 31, 2021 | 32.10 Mn |
| Oct 2, 2021 | -53.90 Mn |